“…This treatment option is offered to patients having early localized prostate cancer (Stage < T2c, Gleason score < 7, and PSA < 10). Biochemical disease‐free survival rates have now been reported for this procedure for extended follow‐up periods 14, 15, 16, 17, 18, 19, 20, 21. Similar results are also available in a Canadian context 22, 23, 24, 25…”